Blincyto: Treatment for acute lymphoblastic leukemia

Blincyto contains Blinatumomab, a bispecific CD19-directed CD3 T-cell engager that binds to CD19 expressed on the surface of cells of B-lineage origin and CD3 expressed on the surface of T cells. The drug treats relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). The medicine is supplied in single-dose vials of 35 mcg to administer intravenously. The active ingredient in the Blincyto 35 mcg is Blinatumomab with inactive ingredients citric acid monohydrate, lysine hydrochloride, polysorbate 80, trehalose dihydrate, and sodium hydroxide. The drug Blinatumomab activates endogenous T cells by connecting CD3 in the T-cell receptor (TCR) complex with CD19 on benign and malignant B cells. One should store this medicine at 2°C to 8°C (36°F to 46°F) and protect the medicine from light until the time of use. One should not freeze. One can buy Blincyto online from several certified suppliers. There are numerous suppliers of generic medicines; if you want to connect with such suppliers, ring us on 18008891064. Tweet